1. Professor Kim De Keersmaecker (KU Leuven, Belgium) is shown.
Credit: KU Leuven – Rob Stevens. 2. In patients with multiple myeloma, the plasma cells in the bone marrow start proliferating malignantly.
20 – 40% of the patients with multiple myeloma have a defect in the ribosome, protein factory of the cell. These patients have a poorer prognosis than patients with intact ribosomes. At the same time, they respond better to a drug that already exists. These are the findings of a study by the Laboratory for Disease Mechanisms in Cancer at KU Leuven, Belgium.
Multiple myeloma (MM, also known as Kahler’s disease) is a blood cancer whereby the plasma cells in the bone marrow start proliferating malignantly. MM cannot be cured and is most common among older people...
Read More
Recent Comments